Clarus Therapeutics Holdings, Inc.

Clarus Therapeutics Holdings, Inc. (Nasdaq: CRXT) is a specialty pharmaceutical company that completed its SPAC merger in 2021, becoming a publicly traded entity after combining with Blue Safari Group Acquisition Corp, a blank-check vehicle sponsored by Blue Safari Capital Management. The company operates in the healthcare and specialty pharma sector, with its commercial focus centered on men's health, including its FDA-approved oral testosterone replacement therapy JATENZO. The 10-Q filing dated August 16, 2021 reflects the company's early post-merger reporting period on Nasdaq. For full filing history, sponsor details, and deal analytics on CRXT and hundreds of other SPAC transactions, sign up for complete data access at SpacDesk.